Opthea Ltd traded at 1.20 this Friday July 1st, increasing 0.10 or 8.64 percent since the previous trading session. Looking back, over the last four weeks, Opthea Ltd gained 9.81 percent. Over the last 12 months, its price fell by 6.27 percent. Looking ahead, we forecast Opthea Ltd to be priced at 1.10 by the end of this quarter and at 1.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.20
Daily Change
8.64%
Yearly
-6.27%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Cochlear 199.63 0.93 0.47% -18.28%
CSL 269.23 0.17 0.06% -5.26%
Fisher & Paykel Healthcare 17.70 -0.14 -0.78% -37.57%
Nanosonics Ltd 3.43 0.07 2.08% -39.18%
Paradigm Biopharmaceuticals Ltd 0.96 -0.01 -1.04% -54.09%
Pacific Edge 0.68 0 0% -44.26%
Pacific Smiles Group Ltd 1.79 -0.02 -0.83% -35.56%
PYC Therapeutics Ltd 0.07 0.001 1.54% -56.00%
Ramsay Health Care 73.00 -0.24 -0.33% 16.19%
ResMed 30.50 -0.19 -0.62% -7.44%
Telix Pharmaceuticals Ltd 4.64 0.11 2.43% -20.14%


Opthea Ltd
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing therapies primarily for eye diseases. The Company's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. It has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.